ArticleMedical journal of the Islamic Republic of Iran2024
The Economic Burden of Cutaneous Leishmaniosis: Report from a Developing Country.
Article in Medical journal of the Islamic Republic of Iran, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cutaneous leishmaniasis: epidemiology, treatment access and translational challenges of topical therapies.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Considering the high prevalence of cutaneous leishmaniasis in tropical and subtropical countries and the urgent need for an economic approach to the treatment sector, this study aimed to investigate the economic burden caused by this disease in Northeast Iran. Methods: This cross-sectional study was conducted on 3558 patients with cutaneous leishmaniasis whose data were registered in the disease surveillance system at Mashhad University of Medical Sciences, Mashhad, Iran. The disease care model was designed from the stage of suspected disease to diagnosis, treatment, treatment/care of disease complications, treatment/care of drug side effects, disease recurrence, and drug resistance. Then, the direct costs were calculated. Results: Overall, 7.5 billion Rials (equal to $750,000) have been spent on providing health care services to 3558 patients with leishmaniasis. The per capita cost of diagnosis/treatment of the disease was 1,600,100 Rials (equal to $160), the per capita cost of care/management was 505,902 Rials (equal to $50), and the per capita cost of cutaneous leishmaniasis disease was calculated as 2,106,002 Rials (equals to $210). Conclusion: Leishmaniosis has a considerable economic burden on society and the healthcare system. Considering that the predisposing factors are avoidable, it is possible to reduce the economic burden by using less expensive and effective solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.